Avails Medical, Inc. is a pioneer in rapid, automated solutions for antibiotic susceptibility testing (AST). Founded by a team of Stanford postdoctoral researchers, Avails’ electronic biosensor technology is designed to improve affordability and speed in pathogen quantification and susceptibility testing directly from human specimens for clinical laboratories by eliminating manual, time-consuming culturing steps. Avails’ eQUANT(TM) platform enables microbiology labs to generate an automated 0.5 McFarland equivalent (eMcF) directly from positive blood cultures (PBC), removing as many as 18+ hours from the standard workflow by eliminating the need for subcultures. The eQUANT system is FDA 510(k) cleared. IN DEVELOPMENT: Avails is also developing a rapid phenotypic AST platform being designed for use directly from PBCs as well as cultured isolates. Avails' electrical biosensor platform fits within the laboratory's existing workflow and budget, serving clinical labs in smaller community hospitals to larger academic centers and centralized laboratories.